ReportWire

Tag: Opioid Use Disorder

  • MBTA balks at expanding overdose prevention kiosks

    BOSTON — MBTA officials are pouring cold water on a legislative push to make the opioid overdose reversing drug naloxone available at subway stations, citing a lack of proper staff and a shortage of funding.

    The T recently wrapped up a federally funded pilot project that installed 15 kiosks with doses of the medicine – also known by its brand name, Narcan – at several Red Line stations to help reduce fatal drug overdoses.


    This page requires Javascript.

    Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

    kAmqFE 😕 2 ?6H C6A@CE E@ E96 {68:D=2EFC6[ E96 42D9DEC2AA65 AF3=:4 EC2?D:E 286?4J D2:5 :E 92D “56E6C>:?65 E92E :E 5@6D ?@E 4FCC6?E=J 92G6 DF77:4:6?E C6D@FC46D @C 2AAC@AC:2E6 A6CD@??6= ?66565 E@ >2?286 E96 52JE@52J 25>:?:DEC2E:@? @7 DF49 2 AC@8C2>]”k^Am

    kAm“%96 |q%p C64@8?:K6D 2?5 DFAA@CED E96 :>A@CE2?46 @7 AC@>@E:?8 92C> C65F4E:@? 677@CED 2?5 :?4C62D:?8 AF3=:4 2446DD E@ =:76D2G:?8 >65:42E:@? E92E 42? C6G6CD6 2? @A:@:5 @G6C5@D6[” {J?D6J w6776C?2?[ E96 %’D 49:67 @7 A@=:4J U2>Aj DEC2E68:4 A=2??:?8[ HC@E6 😕 E96 C6A@CE] “x? E96 6G6?E DE277:?8 2?5 AC@8C2> >2?286>6?E 42? 36 >256 2G2:=23=6 7C@> 2 E9:C5 A2CEJ[ E96 |q%p 42? 4@?E:?F6 E@ >2<6 DA246 2G2:=23=6 😕 :ED 724:=:E:6D E@ DFAA@CE E96 AC@8C2>]”k^Am

    kAm(9:=6 |q%p %C2?D:E !@=:46 92G6 2?5 H:== 4@?E:?F6 E@ 42CCJ ?2=@I@?6[ E96 % C64@>>6?565 E92E 2?J 7FEFC6 AF3=:4 2446DD AC@8C2> 😕 @C ?62C DE2E:@?D 36 “>2?2865 3J 2 E9:C5 A2CEJ” H9@D6 >:DD:@? “:D 2=:8?65 H:E9 DF49 2? :>A@CE2?E AC@8C2> 2?5 E92E 92D E96 C6D@FC46D 2?5 A6CD@??6= E@ >@?:E@C 2?5 C6DFAA=J ?2=@I@?6 2D H6== 2D E@ >2?286 7@C E6>A6C2EFC6 7=F4EF2E:@?D]”k^Am

    kAm%96 C6A@CE 4@>6D 2D q624@? w:== =2H>2<6CD AFD9 A2DD286 @7 =68:D=2E:@? E92E 42==D 7@C >2<:?8 E96 A:=@E AC@8C2> A6C>2?6?E 24C@DD E96 %’D DF3H2J DJDE6>] %96 =68:D=2E:@?[ :7 2AAC@G65[ H@F=5 C6BF:C6 |q%p DE2E:@?D E@ 92G6 2E =62DE EH@ “7C66DE2?5:?8 F?2=2C>65 ?2=@I@?6 3@I6D” 6249 4@?E2:?:?8 EH@ F?:ED @7 E96 @G6C5@D6C6G6CD:?8 DAC2J 2G2:=23=6 7@C AF3=:4 FD6]k^Am

    kAm“uC2?<=J[ x 36=:6G6 6G6CJ 3FD 2?5 4@>>FE6C C2:= 42C D9@F=5 92G6 ?2=@I@?6[” DE2E6 $6?] y@9? z6??2?[ 2 “F:?4J s6>@4C2E 2?5 E96 3:==’D AC:>2CJ DA@?D@C[ D2:5 😕 E6DE:>@?J 367@C6 E96 {68:D=2EFC6’D r@>>:EE66 @? %C2?DA@CE2E:@? 62C=:6C E9:D >@?E9] “xE D9@F=5 36 2D 4@>>@? 2D 7:C6 6IE:?8F:D96CD 2?5 =:89E 3F=3D]”k^Am

    By Christian M. Wade | Statehouse Reporter

    Source link

  • Rockport school board updated on opioid prevention

    The Rockport School Committee, along with the town’s Public Health Department, is aiming to eliminate the effects of possible substance abuse in Rockport schools.

    During the committee’s meeting on June 4, members heard from Dr. Ray Cahill, director of the Rockport Public Health Department, who updated those gathered about the “RIZE Mosaic Opioid Recovery Partnership Grant.” The grant aims to support children and families affected by the opioid crisis.


    This page requires Javascript.

    Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

    kAm%96 8C2?E AC@8C2> 😀 2 ?6H :?:E:2E:G6 7@4FD65 @? 96=A:?8 E9@D6 724:?8 @A:@:5 255:E:@? AC@3=6>D[ r29:== D2:5]k^Am

    kAm“|F?:4:A2=:E:6D 24C@DD E96 4@>>@?H62=E9 92G6 366? 23=6 E@ 2AA=J 7@C @?6J62C >2E49:?8 8C2?ED[” 96 D2:5[ 255:?8 E92E A2CE @7 E96 :?:E:2E:G6 DEC:G6D E@ C65F46 E96 DE:8>2D 2DD@4:2E65 H:E9 @A:@:5 23FD6 2?5 7@DE6C 2 >@C6 DFAA@CE:G6 2?5 :?7@C>65 6?G:C@?>6?E C6=2E65 E@ “@A:@:5 FD6 5:D@C56C]”k^Am

    kAm“%96 E9C66 4@>>F?:E:6D A@@=65 S`d_[___ 2?5 E92E H2D >2E4965[” 96 D2:5] “$@[ E96 E@E2= 8C2?E 😀 Sb__[___]”k^Am

    kAm%96 8C2?E 😀 >2?2865 3J E96 #x+t |2DD249FD6EED u@F?52E:@?[ 2 q@DE@? ?@?AC@7:E 565:42E65 E@ 7F?5:?8 2?5 4C62E:?8 D@=FE:@?D E@ 6?5 E96 @G6C5@D6 4C:D:D 😕 |2DD249FD6EED]k^Am

    kAm“%96 @G6C2C49:?8 8@2= @7 E9:D :?:E:2E:G6 😀 H6 2C6 H@C<:?8 E@ 56G6=@A 2? 64@DJDE6> H96C6 H6 42? C65F46 32CC:6CD E92E :?5:G:5F2=D 7246 H96? E96J’C6 D66<:?8 EC62E>6?E 2?5 C64@G6CJ D6CG:46D[” r29:== D2:5]k^Am

    kAmp 4@>>F?:EJ DFCG6J H2D C646?E=J 4@?5F4E65 @? r2A6 p??[ 96 D2:5[ H9:49 :?5:42E65 E96 7@==@H:?8 E@A 32CC:6CD E@ DF3DE2?46 23FD6 C64@G6CJ AC@8C2>Dik^Am

    kAm %96 4@DE @7 D@36C =:G:?8 AC@8C2>Dk^Am

    kAm %96 4@DE @7 AC6D4C:AE:@? 5CF8D FD65 😕 EC62E>6?Ek^Am

    kAm p446DD 2?5 4@DE C6=2E65 E@ EC2?DA@CE2E:@? E@ >65:42= 2AA@:?E>6?ED 2?5 >65:42= 724:=:E:6Dk^Am

    kAm $E:8>2D C6=2E65 E@ @A:@:5 FD6 5:D@C56Ck^Am

    kAm“xE H2D G6CJ 4=62C H92E E96 E@A 92?57F= @7 32CC:6CD H6C6[” r29:== D2:5]k^Am

    kAm!2CE @7 E96 677@CE ?@H H:== :?4=F56 2 4@>>F?:EJ @FEC6249 AC@46DD E@ D92C6 :?7@C>2E:@? 23@FE E96 8C2?E AC@8C2> E9C@F89@FE E96 4@>>F?:EJ[ 96 D2:5]k^Am

    kAmr29:== 5:5 A@:?E @FE E92E E96 :?:E:2E:G6 😀 ?@E D66? 2D 2 A2?2462 7@C 2== AC@3=6>D C6=2E65 E@ DF3DE2?46 23FD6]k^Am

    kAm“%96C6’D ?@E 2 @?6D:K67:ED2== D@=FE:@? H96? :E 4@>6D E@ 255:4E:@?[” 96 D2:5] “%96C6’D 2 3C@25 DA64ECF> @7 ?665D] x7 H6’C6 8@:?8 E@ 92G6 2 D:8?:7:42?E :>A24E[ H6 ?665 E@ 36 E2=<:?8 23@FE E9:D 2?5 H6 ?665 E@ 36 A@@=:?8 @FC C6D@FC46D 2?5 A@@=:?8 @FC E9@F89ED]k^Am

    kAm“xE’D C62==J E96 @?=J A2E9 E@ 4@>:?8 FA H:E9 4@?DECF4E:G6 @AA@CEF?:E:6D 7@C :?E6CG6?E:@?] z66A:?8 J@FE9 D276 😀 A2C2>@F?E]”k^Am

    kAmk6>m$E6A96? w282? 42? 36 C624965 2E hfgefdaf_g @C 2E k2 9C67lQ>2:=E@iD9282?o8=@F46DE6CE:>6D]4@>QmD9282?o8=@F46DE6CE:>6D]4@>k^2m]k^6>mk^Am

    By Stephen Hagan | Staff Writer

    Source link

  • Data: Fewer opioids prescribed in Mass., NH

    Data: Fewer opioids prescribed in Mass., NH

    BOSTON — While the scourge of opioid addiction continues to affect Massachusetts, the number of people getting legal prescriptions for heavily addictive medicines is falling, according to the latest federal data.

    Massachusetts had the second lowest opioid prescription rate in New England in 2022, following Vermont, the U.S. Centers for Disease Control and Prevention reported. Health care providers in the Bay State wrote 30.8 opioid prescriptions for every 100 residents, the federal agency reported.

    That’s a slight drop from the previous year but a substantial decline from the 66 per 100 prescription rate in 2006, when the CDC began tracking the data, which lags by two years.

    New Hampshire, which has also seen declining numbers of opioid prescriptions in recent years, had the third-lowest rate in New England in 2022, with 32 prescriptions for every 100 residents. Maine had the highest rate in the region, or 35.2 per 100 residents.

    Nationally, the overall prescription rate was 39.5 prescriptions per 100 people in 2022, according to the CDC data.

    Curbing opioid addiction has been a major focus on Beacon Hill for a number of years, with hundreds of millions of dollars being devoted to expanding treatment and prevention efforts.

    For many, opioid addiction has its roots in prescription painkillers such as Oxycontin and Percocet, which led them to street-bought heroin and fentanyl once those prescriptions ran out.

    In 2016, then-Gov. Charlie Baker and lawmakers pushed through a raft of rules to curb over-prescribing of opioids. Those included a cap on new prescriptions written in any seven-day period and a requirement that doctors consult a state prescription monitoring database before prescribing an additive opioid.

    Meanwhile opioid manufacturers have been hammered with hundreds of lawsuits from the states and local governments over their role in fueling a wave of opioid addiction. Attorney General Maura Healey’s office recently agreed to a multi-billion dollar settlement with OxyContin maker Purdue Pharma.

    Supporters of the tougher requirements say they have saved lives by dramatically reducing the number of heavily addictive opioids being prescribed.

    Pain management groups say the regulatory backlash has made some doctors worried about writing prescriptions for opioids, depriving patients of treatment.

    There were 2,125 confirmed or suspected opioid-related deaths in 2023 — which is 10%, or 232, fewer fatal overdoses than the same period in 2022, according to the latest data from the state Department of Public Health.

    Last year’s opioid-related overdose death rate also decreased by 10% to 30.2 per 100,000 people compared with 33.5 in 2022, DPH said.

    Health officials attributed the persistently high death rates to the effects of an “increasingly poisoned drug supply,” primarily with the powerful synthetic opioid fentanyl. Fentanyl was present in 90% of the overdose deaths where a toxicology report was available, state officials noted.

    Nationally, there were 107,543 overdose deaths reported in the U.S. in 2023, a 3% decrease from the estimated 111,029 in 2022, according to CDC data.

    On Beacon Hill, state lawmakers are being pressured to take more aggressive steps to expand treatment and prevention options for those struggling with opioid addiction.

    Last month, a coalition of more than 100 public health and community-based organizations wrote to House and Senate leaders urging them to pass substance abuse legislation before the Dec. 31 end of the two-year session.

    “There isn’t a day that goes by without several people in the Commonwealth dying from an overdose or losing loved ones to this disease,” they wrote. “As individuals and institutions working to combat the opioid epidemic, we know the Commonwealth must do more to prevent addiction, help people find pathways to treatment and recovery, and save lives.”

    Christian M. Wade covers the Massachusetts Statehouse for North of Boston Media Group’s newspapers and websites. Email him at cwade@cnhinews.com.

    By Christian M. Wade | Statehouse Reporter

    Source link

  • Data: Fewer opioids prescribed in Massachusetts

    Data: Fewer opioids prescribed in Massachusetts

    BOSTON — While the scourge of opioid addiction continues to affect Massachusetts, the number of people getting legal prescriptions for heavily addictive medicines is falling, according to the latest federal data.

    Massachusetts had the second lowest opioid prescription rate in New England in 2022, following Vermont, the U.S. Centers for Disease Control and Prevention reported. Health care providers in the Bay State wrote 30.8 opioid prescriptions for every 100 residents, the federal agency reported.

    That’s a slight drop from the previous year but a substantial decline from the 66 per 100 prescription rate in 2006, when the CDC began tracking the data, which lags by two years.

    New Hampshire, which has also seen declining numbers of opioid prescriptions in recent years, had the third-lowest rate in New England in 2022, with 32 prescriptions for every 100 residents. Maine had the highest rate in the region, or 35.2 per 100 residents.

    Nationally, the overall prescription rate was 39.5 prescriptions per 100 people in 2022, according to the CDC data.

    Curbing opioid addiction has been a major focus on Beacon Hill for a number of years, with hundreds of millions of dollars being devoted to expanding treatment and prevention efforts.

    For many, opioid addiction has its roots in prescription painkillers such as Oxycontin and Percocet, which led them to street-bought heroin and fentanyl once those prescriptions ran out.

    In 2016, then-Gov. Charlie Baker and lawmakers pushed through a raft of rules to curb over-prescribing of opioids. Those included a cap on new prescriptions written in any seven-day period and a requirement that doctors consult a state prescription monitoring database before prescribing an additive opioid.

    Meanwhile opioid manufacturers have been hammered with hundreds of lawsuits from the states and local governments over their role in fueling a wave of opioid addiction. Attorney General Maura Healey’s office recently agreed to a multi-billion dollar settlement with OxyContin maker Purdue Pharma.

    Supporters of the tougher requirements say they have saved lives by dramatically reducing the number of heavily addictive opioids being prescribed.

    Pain management groups say the regulatory backlash has made some doctors worried about writing prescriptions for opioids, depriving patients of treatment.

    There were 2,125 confirmed or suspected opioid-related deaths in 2023 — which is 10%, or 232, fewer fatal overdoses than the same period in 2022, according to the latest data from the state Department of Public Health.

    Last year’s opioid-related overdose death rate also decreased by 10% to 30.2 per 100,000 people compared with 33.5 in 2022, DPH said.

    Health officials attributed the persistently high death rates to the effects of an “increasingly poisoned drug supply,” primarily with the powerful synthetic opioid fentanyl. Fentanyl was present in 90% of the overdose deaths where a toxicology report was available, state officials noted.

    Nationally, there were 107,543 overdose deaths reported in the U.S. in 2023, a 3% decrease from the estimated 111,029 in 2022, according to CDC data.

    On Beacon Hill, state lawmakers are being pressured to take more aggressive steps to expand treatment and prevention options for those struggling with opioid addiction.

    Last month, a coalition of more than 100 public health and community-based organizations wrote to House and Senate leaders urging them to pass substance abuse legislation before the Dec. 31 end of the two-year session.

    ”There isn’t a day that goes by without several people in the Commonwealth dying from an overdose or losing loved ones to this disease,” they wrote. “As individuals and institutions working to combat the opioid epidemic, we know the Commonwealth must do more to prevent addiction, help people find pathways to treatment and recovery, and save lives.”

    Christian M. Wade covers the Massachusetts Statehouse for North of Boston Media Group’s newspapers and websites. Email him at cwade@cnhinews.com.

    By Christian M. Wade | Statehouse Reporter

    Source link

  • Orange County overdose prevention program aims to save lives, one fentanyl test strip at a time

    Orange County overdose prevention program aims to save lives, one fentanyl test strip at a time

    click to enlarge

    Courtesy of Largest Heart

    Nonprofit Largest Heart distributes fentanyl test strips in Orange County to help prevent accidental overdose.

    When Peter Cook was in the throes of alcoholism seven years ago, he didn’t imagine he would eventually work to help others who similarly lived and suffered from addiction. In 2017, Peter’s brother Andrew gave him the push and resources he needed to get help and begin his path towards recovery.

    Just weeks after, however, Andrew unexpectedly passed away in southern Chile, while on vacation. According to his obituary, Andrew was just 39 years old, a “dedicated Christian” and an English teacher.

    For Peter, a resident of Winter Garden, his brother’s sudden passing was a tragedy that led him to where he is today, working by day as the Director of Business Development for Central Florida Behavioral Hospital and as head of a local nonprofit. “Where passion meets purpose,” he told Orlando Weekly.

    On his brother’s birthday, in August 2018, Cook officially formed his local nonprofit organization, Largest Heart, a grassroots harm reduction project. Cook “literally Googled ‘how to start a nonprofit,’” he admitted sheepishly, but also with pride.

    Earlier this year, Largest Heart was one of two organizations, along with Project Opioid, that was chosen by the Orange County government to lead a new effort to prevent accidental drug overdose.

    Over the last decade, fatal drug overdoses in the county have surged more than 250 percent, from 175 deaths in 2014 to roughly 450 last year. A majority are tied to illicit forms of the opioid fentanyl, which is largely coming from U.S. citizens (not migrants) smuggling it across legal points of entry at the U.S. Southern Border, according to immigration authorities.

    The idea of Largest Heart’s project, called “Test Before You Try,” is to expand access to fentanyl test strips: small, inexpensive paper strips that can tell you whether there is fentanyl in your drugs. They’re simple to use, about 96 to 100 percent accurate when used correctly, and can save lives.

    Until last year, these strips were technically illegal to have, sell or give away in Florida, simply due to being classified under old state statutes as “drug paraphernalia.” State lawmakers in Florida, and over two dozen other states with similar statutes on the books, however, have altered their state laws on paraphernalia in recent years to change that.

    So far, Largest Heart has distributed over 38,000 fentanyl testing kits throughout the county, which (thanks to a partnership with DanceSafe) contain testing strips as well as instructions for how to use them.

    Cook stressed that distributing these kits is not a push to use drugs — “We don’t encourage drug use,” he affirmed — but to make sure that if you, a friend or a roommate does use, they’re doing so safely, without risking their life. “It’s an empowerment program,” he explained.

    Fentanyl, a synthetic opioid up to 50 times more potent than the illicit opioid heroin, has driven the country’s overdose crisis in recent years, killing nearly 75,000 people in the U.S. last year alone.

    It can happen to anyone

    What’s most dangerous about this potent drug is where it’s being found. Lab testing from the U.S. Drug Enforcement Administration (DEA) found that 7 out of every 10 counterfeit pills they seized last year contained a lethal dose of fentanyl.

    Just two milligrams, comparable to just a few grains of table salt, can be deadly. And it’s been found laced into a wide range of illegally produced drugs, including drugs like cocaine, meth, fake pills marketed by dealers under different names, and unregulated forms of marijuana.

    What Largest Heart is attempting to do is “not condemning somebody for making a bad decision,” said Cook, referring to illicit drug use, “but educating them.” Making sure that if someone does choose to take a pill at a party or smoke a blunt, they’re not unknowingly putting their life on the line. Substance use experts have warned that you don’t have to have a drug addiction or even regularly use drugs in order to accidentally lose your life.

    You can be a teenager or college student who, facing peer pressure, takes a pill someone hands you at a party. You’re told it’s Xanax — a central nervous system depressant commonly prescribed for anxiety — but it’s not. You don’t know this, of course, so you take the pill. Your limbs become heavy. Your face becomes clammy, pale or ashen. Your breathing slows, then stops. You lose consciousness. And you never wake up.

    It’s not just a Lifetime movie or some D.A.R.E ad. It’s an actual horror story playing out across the country, quietly devastating parents, friends and communities. Although drug use among youth, specifically, has declined in recent years, teen overdose rates have surged. Counterfeit prescription pills containing fentanyl are believed to be a contributing cause.

    Although drug use among youth has declined in recent years, teen overdose rates have surged.

    tweet this Tweet This

    According to data from the Orange County Medical Examiner’s Office, reviewed by Orlando Weekly, at least four teenagers in Orange and Osceola Counties have died of drug overdose this year alone. All four deaths involved fentanyl, and were marked as accidental deaths. In total, the office has identified 263 drug-involved deaths in Orange and Osceola counties this year so far, with fentanyl specifically involved in the vast majority.

    “Anytime somebody buys a pill off the street, they should assume it’s more likely that it’s contaminated with fentanyl,” Dr. Thomas Hall, director of the Orange County Office for a Drug-Free Community, told Orlando Weekly earlier this year.

    Several adults who died of fatal drug overdose this year were identified by the Medical Examiner’s Office as “transient,” meaning they were homeless. But the vast majority of people who died had a listed home address.

    Overdose deaths surged dramatically during the COVID-19 pandemic, as people found themselves cut off from others, struggling with mental health, and more vulnerable to using drugs and alcohol to cope. Those who used drugs were also more likely to use them alone, and therefore did not have someone around to call 911 or administer Narcan (a life-saving opioid overdose reversal drug) if they collapsed.

    In Orange County, drug overdose deaths reached their peak in 2021. More than 500 people died of drug overdose that year, up from 172 deaths in 2014 and 342 deaths in 2019. The number of fatal overdoses has declined some since, with a slight increase documented last year, but the number of lives lost has remained above pre-pandemic levels.

    “We’ve never seen anything like it,” said Cook. “We’re gonna lose a generation of kids to deadly fentanyl.”

    A community effort

    The fentanyl test strip distribution effort led by Cook’s nonprofit Largest Heart is being funded by a small portion of what Orange County has received so far through national settlements with opioid manufacturers and distributors.

    Altogether, the county will receive an estimated $60 million payout from those settlements, distributed over the next 15 to 18 years. The county has already earmarked funds for projects such as overdose awareness campaigns for adults and youth, a mobile medication-assisted treatment clinic for opioid addiction (expected to launch next month), and a new addiction treatment program that just launched this month in Parramore for uninsured residents.

    Project Opioid, an Orlando-based profit also focused on reducing overdose deaths, has also received funds to distribute fentanyl test strips. They’re focusing on passing out fentanyl test strips downtown outside nightclubs and bars on the weekends.

    Largest Heart’s program has been approved for $61,000 in funding, according to Cook, which comes through reimbursement from the county. “Largest Heart pays for this all upfront,” said Cook, who admitted they’re operating “on a shoestring budget.”

    Since March, Largest Heart has been passing out fentanyl test strip kits at community events, including 8,000 at Orlando’s Juneteenth Celebration, and has also given them away to local businesses or organizations that ask, such as food pantries and the LGBT+ Center Orlando.

    It’s become a community effort. Park Ave CDs, one of Orlando’s most beloved indie music retailers, has been “one of our best community partners,” Cook gushed. “They are so about protecting and loving on this community in Orlando. It’s absolutely amazing.”

    click to enlarge An Instagram post from Park Ave CDs promoting harm reduction supplies the store gives out to help keep the community safe. - Park Ave CDS/Instagram

    Park Ave CDS/Instagram

    An Instagram post from Park Ave CDs promoting harm reduction supplies the store gives out to help keep the community safe.

    Another surprise: “Law enforcement loves them,” he added. The library system is also interested in getting kits to pass out, and local schools, grappling with their own role in preventing accidental overdose among students, have also shown interest. “We had elementary schools requesting these,” Cook said.

    Not having an advertising budget for Test Before You Try, he admitted, is one of their biggest challenges in spreading the word. In addition to fentanyl test strips, they’ve also distributed Narcan, the opioid overdose reversal medication. Narcan, or its generic version naloxone, can be purchased from places like Publix, or you can get it for free at different access sites throughout the state, or request it via mail.

    Beyond distribution, the idea is to reduce stigma and create openings for conversations about drug use and harm reduction. It could ultimately be a cost-saving effort, too. When or if someone overdoses, the ambulance costs, healthcare costs and other criminal justice system costs can add up for communities.

    Similarly, drug addiction can result in lost productivity, health conditions and reduced quality of life, and becomes more costly to treat as conditions become more severe or chronic. Nationally, fatal opioid overdose can cost hundreds of billions of dollars each year, research has found, while treatment for addiction and harm reduction strategies such as fentanyl test strips can be more cost-effective.

    Cook’s organization recently secured an agreement with Volusia County to expand their fentanyl test strip distribution there. He’s currently in talks with the Osceola County government as well, saying, “My goal is to take this statewide.”

    He’s been speaking with state legislators in the area who might be interested in sponsoring a request for state funds. One of them is Democratic Sen. Geraldine Thompson, who hosted the city’s Juneteenth celebration in Orlando. A legislative aide for Thompson confirmed the senator is considering the request, but has not yet made a decision on whether to sponsor.

    Cook admitted, due to stigma, sometimes you have to craft your pitch for fentanyl test strip kits on the fly, depending on who you’re talking to. But it’s not always hard. Cook said one grandmother came up to him at an event his nonprofit attended and cried on his shoulder, thanking him for his work. Her teenage grandson had died, he recalled, after smoking marijuana laced with fentanyl.

    For a young person headed to college who doesn’t use drugs, and doesn’t plan to, he explains to them, “This isn’t for you. This is for your roommate.” For parents, he tells them, “Like, I know your kid’s never gonna smoke weed, but if they do, here you go.”

    Ultimately, it’s laying out the stakes: Thousands of people die of accidental overdose each year. And you never know who could be next.

    click to enlarge Florida Sen. Tina Polsky hugging Democratic colleague Sen. Lori Berman after a bill to decriminalize fentanyl testing equipment passes on March 29, 2023. - The Florida Channel

    The Florida Channel

    Florida Sen. Tina Polsky hugging Democratic colleague Sen. Lori Berman after a bill to decriminalize fentanyl testing equipment passes on March 29, 2023.

    Need help?

    September is National Recovery Month. If you or a loved one is struggling with substance misuse, you’re not alone.

    Subscribe to Orlando Weekly newsletters.

    Follow us: Apple News | Google News | NewsBreak | Reddit | Instagram | Facebook | Twitter | or sign up for our RSS Feed

    McKenna Schueler

    Source link

  • Orange County opens new medication-assisted treatment program for opioid addiction

    Orange County opens new medication-assisted treatment program for opioid addiction

    click to enlarge

    Orange County Government media gallery

    Orange County’s Office for a Drug-Free Community leads efforts to curb opioid deaths through prevention education, enforcement, treatment and recovery.

    Just west of downtown Orlando on Westmoreland Street, the Orange County Medical Clinic has launched a new medication-assisted treatment program in partnership with a nonprofit treatment provider for uninsured residents with opioid use disorder.

    The program, funded by money that Orange County received through national settlements with opioid manufacturers and distributors, is available at no cost, and is designed for people with chronic or severe addiction who lack the resources to access treatment otherwise.

    People who were recently released from jail or who have ended up in local hospital emergency rooms multiple times for overdose, will be prioritized for the program, which is launched in partnership with Specialized Treatment Education and Prevention Service.

    “The whole point of this is to provide access to people who wouldn’t typically have access to care,” Dr. Thomas Hall, director of the county’s Office for a Drug Free Community, told Orlando Weekly. Both repeat overdoses and a history of incarceration are known risk factors for fatal opioid overdose, which can be identified by signs such as slowed or stopped breathing, pale or clammy skin, or loss of consciousness.

    “The whole point of this is to provide access to people who wouldn’t typically have access to care”

    tweet this Tweet This

    The steep cost of quality addiction treatment — hundreds or thousands of dollars for those who lack insurance — and a lack of knowledge about available community resources can be major barriers to getting help, Hall added. “Do they know how to get treatment? Do they know where they can get it? We’re trying to market to that group that there’s care available.”

    The goal is to mitigate a crisis that began with addictive prescription opioids like OxyContin in the late ’90s, before a crackdown on such drugs led those with addiction to street drugs like heroin, and now fentanyl, a powerful (and potentially deadly) opioid that can be prescribed for certain pain conditions, but is also manufactured and sold on the black market.

    Medication-assisted treatment, a program that refers to a combination of behavioral therapy and medication, is the most effective treatment for opioid addiction, more formally referred to as opioid use disorder. Studies have found that certain medications can significantly reduce the risk of opioid overdose and prevent death among those ingest opioids, yet only a quarter of people with opioid use disorder actually receive it.

    Dr. Hall said medication-assisted therapy, effective for people addicted to opioid painkillers, can serve as a “bridge” for people in the early stages of recovery. “[Medication-assisted treatment] is more effective in treating an opioid use disorder than individual therapy and self-help groups alone,” Hall explained.

    It’s a holistic approach to treatment that has gradually received more support from treatment providers and the U.S. government over the years, with more evidence emerging to dispel the myth that MAT simply trades one addiction for another. The length of treatment can vary depending on each person’s individual needs, and may range from months, to years for some, if that’s considered by treatment providers to be the best option for continued stability.

    Buprenorphine, a “gold standard” medication for opioid use disorder that the new program in Orange County offers, can specifically help curb drug cravings and can ease uncomfortable drug withdrawal symptoms, according to Hall.

    There are three medications that are approved by the U.S. Federal Drug Administration (FDA) to treat opioid addiction: Buprenorphine (also known as Suboxone, when combined with naloxone), methadone, and naltrexone (the generic name for Vivitrol).

    Methadone, a long-acting opioid that can be safely administered to treat addiction, is strictly regulated by the federal government, and requires visiting a clinic daily, while naltrexone has delivered spotty results.

    Orange County’s medical clinic, located at 101 S. Westmoreland Drive, will primarily be offering buprenorphine and Suboxone for addiction, according to Hall, although Vivitrol will also be available. Access to buprenorphine, a partial opioid agonist that prevents a person from getting high off other opioids, was made easier last year under the Biden-Harris administration, which eliminated a bureaucratic hurdle known as the “X Waiver.”

    Prior to the elimination of that waiver requirement, doctors had to undergo an intensive (and burdensome) approval process in order to be able to prescribe the life-saving drug. Research found just 5 percent of medical providers had been licensed to prescribe it, prior to the elimination of the waiver requirement, creating vast treatment deserts across the country for those in need.

    Treatment has historically been less accessible for people of color with addiction (who face additional barriers to care, such as stigma) and for rural communities with fewer providers. The stakes of lacking access to treatment and other protective resources, such as social support from family or friends, are high.

    Overdose deaths involving opioids in Orange County nearly doubled over a five-year period, from 175 deaths in 2014 to 342 deaths in 2019. The problem, mostly driven by the highly potent opioid fentanyl, worsened during the COVID-19 pandemic, as people suffered from isolation, stress, job loss, and disruptions in access to care.

    To prevent spread of the virus, treatment centers closed their doors or placed restrictions on the number of patients they could accept. In-person support groups shuttered, or moved online. Naloxone, a drug capable of reviving someone who’s overdosed on opioids, became less accessible.

    Stress drove some in recovery during the pandemic to pick up a bottle — of booze, drugs, or other substances — to cope. People during COVID used drugs alone, instead of in pairs or groups, thereby increasing the risk that, if someone did overdose, no one would be around to revive them.

    More than 106,000 people in the United States died of overdose in 2021 — a record high number that rippled through communities. Since then, the number of annual overdose deaths has slowly decreased nationally, but data shows that thousands of people in Florida still lose their lives to fatal overdose each year, resulting in devastation for the loved ones, parents, and friends they leave behind.

    In Central Florida, Orange County saw its first small drop in overdose deaths in 2022, according to data from the Medical Examiner’s Office, followed by a small increase the following year.

    Hall said that fentanyl, a drug that can be deadly in very small amounts, is still the primary driver of overdoses locally, even with the infiltration in local drug supplies of other powerful substances like nitazenes (a class of synthetic pain relievers that have never been approved for use in the United States).

    Fentanyl, a drug up to 50 times stronger than heroin, is often mixed in with other street drugs, such as cocaine, and may be marketed as a different drug entirely — including black market versions of Xanax or Klonopin (prescription drugs commonly taken for anxiety).

    The county has identified certain trends in who’s most greatly impacted. One in five overdose deaths in Orange County occur among people who were recently released from the local jail, according to Hall. Compared to the general public, incarcerated people are at least 40 to 129 times as likely to die from drug overdose within weeks of their release. Research has found that overdose is the leading cause of death for anyone recently released from jail or prison.

    These statistics encouraged Orange County to become the first county in Florida to offer medication-assisted treatment inside its local jail, but Hall admitted that a person’s success in maintaining recovery following release isn’t guaranteed.

    A lack of social support, triggers to use at home, or limited employment and housing opportunities can all factor into a person’s risk for relapse. “If somebody is not housed, if they don’t have friends, they don’t have social support of others, it’s a lot easier to relapse,” said Hall, who has over 25 years of experience as a mental health and addiction treatment provider.

    Cheryl Bello, chief executive officer of STEPS, told Orlando Weekly earlier this year that lacking reliable transportation and childcare — an increasingly steep expense for families — can also serve as barriers to continued treatment, particularly for mothers with addiction.

    According to a county news release, the clinic’s new MAT program in Parramore will offer telehealth services for patients, in addition to in-person care, to help meet people where they’re at. Patients can be referred to the program by a treatment or social services provider, or call the clinic for more information about enrollment.

    The program, which will begin as a one-year pilot, is being funded by $1 million in funds the county received through national settlements with opioid manufacturers and distributors accused of flooding communities with drugs they knew were highly addictive.

    Hall said the program in Parramore could continue past one year, if they demonstrate success, but the county would likely have to pitch in its own government funds for that to happen.

    Altogether, the county will receive an estimated $60 million over the next 15 years from those national opioid settlements, with much of that scheduled to come in within the first 10 years. The bulk of funds — 85 percent — must be spent on addiction treatment and prevention programs, under stipulations of the agreements.

    In addition to the new medication-assisted treatment program in Parramore, Orange County leaders earlier this year also allocated settlement funds for:

    • The distribution of fentanyl test strips (which can detect fentanyl in street drugs, and help prevent accidental overdose)

    • A mobile medication-assisted treatment clinic (expected to launch next month, according to Hall)

    • a no-cost residential treatment program for low-income women with opioid use disorder who are either pregnant or are new moms

    • Care coordination services at select Orlando Health hospitals, to help connect people who end up in the ER for overdose to appropriate treatment and aftercare

    Find treatment for addiction

    Opioid use disorder affects more than two million people in the United States. If this describes you, you’re not alone. And you have options.

    If you or a loved one is struggling with opioid addiction, you can learn more about Orange County’s new treatment program by calling the MAT Clinic at (407) 955-7710.

    Additional resources for identifying addiction and finding help:

    Subscribe to Orlando Weekly newsletters.

    Follow us: Apple News | Google News | NewsBreak | Reddit | Instagram | Facebook | Twitter | or sign up for our RSS Feed

    McKenna Schueler

    Source link

  • Sheriff expands inmate drug treatment program to The Farm

    Sheriff expands inmate drug treatment program to The Farm

    LAWRENCE — Sheriff Kevin Coppinger plans to stand before hundreds of police chiefs this month and tell them how he’s bringing drugs into Essex County jails.

    It may sound odd as keeping illicit drugs and contraband out of jails and prisons will always be an issue, Coppinger noted.

    But Middleton Jail now has a nationally acclaimed Medication Assisted Treatment (MAT) program where addicted inmates can receive their medically prescribed doses of Suboxone, methadone and Vivitrol on a daily basis.

    In large part, such doses are used to treat the opioid addiction that has plagued the region for the past two decades. And many local crimes are drug driven.

    Last week, the MAT program expanded when a second treatment site opened at an Essex County Sheriff’s Department location — The Correctional Alternative Center, known as The Farm, off Marston Street in Lawrence.

    Adding a second MAT unit “allows us to get the medication to the inmates easier and increases public safety in the community,” Coppinger said.

    About two-thirds of Essex County inmates are diagnosed with both substance abuse and mental health disorders. The sheriff’s department was housing 819 inmates as of Friday’s count.

    At Middleton Jail, 180 inmates receive MAT. About another 35 are treated through MAT at The Farm, which includes females from the Women In Transition program, who are driven there from the Salisbury facility.

    “Abundant evidence” shows the drugs used in MAT programs “reduce opioid use and opioid use disorder-related symptoms, and they reduce the risk of infectious disease transmission as well as criminal behavior associated with drug use,” according to the National Institute on Drug Abuse.

    “These medications also increase the likelihood that a person will remain in treatment, which itself is associated with lower risk of overdose mortality, reduced risk of HIV and Hepatitis C transmission, reduced criminal justice involvement, and greater likelihood of employment,” the institute reports.

    The roots of the MAT program at Middleton came after a 2018 federal lawsuit by an inmate, Geoffrey Pesce, who had been medically treated with methadone prior to his arrest and jailing for driving without a license.

    Pesce, along with the American Civil Liberties Union of Massachusetts and a law firm, successfully sued for his access to methadone while at Middleton Jail.

    In the lawsuit, the federal court was asked to require ECSD to provide Pesce with the prescribed medication onsite or to transport him daily to a medical facility where he could get his daily dosage.

    “Pesce suffered opioid use disorder and had been in recovery for two years with help of doctor-prescribed medication,” the ACLU of Boston said. “Pesce struggled with addiction for nearly six years, experiencing unemployment, homelessness, and estrangement from his family and son. After his doctor prescribed medication-assisted treatment, he made a dramatic recovery.”

    The hope is with the continued treatment behind bars, individuals won’t want to seek drugs when they are released. Brooke Pessinis, a licensed mental health counselor affiliated with the MAT program, said the goal is “harm reduction” and readying the inmate for success when they leave lock up.

    The inmates are also given Narcan, a medication which can reverse an opioid overdose, when they leave, ECSD Assistant Superintendent Jason Faro said.

    The medication dispensed in MAT are “highly managed” and kept in a safe approved by the Drug Enforcement Administration, he said.

    “You’d probably need 100 sticks of dynamite to blow the door off of it,” Faro said of the safe.

    In October, the MAT program will be among discussion topics at the International Association of Chiefs of Police Conference being held this year in Boston.

    But off stage, anecdotally, on a local level, Faro said he has seen the benefits of the MAT program through a former inmate he occasionally runs into in the Merrimack Valley. The man has a lengthy criminal record that stretches back to when he was 17.

    After MAT treatment and release, the man has now reconnected with his family and children, obtained his commercial drivers’ license and appears to be thriving.

    Notably, Faro said his crimes were “all driven by drug use.”

    Follow staff reporter Jill Harmacinski on Twitter @EagleTribJill.

    By Jill Harmacinski | Staff Writer

    Source link

  • Opioid deaths drop 10%, but remain high

    Opioid deaths drop 10%, but remain high

    BOSTON — The scourge of opioid addiction continues to affect Massachusetts, but new data shows a double-digit decrease in the number of overdose deaths in the past year.

    There were 2,125 confirmed or suspected opioid-related deaths in 2023 — which is 10%, or 232, fewer fatal overdoses than during the same period in 2022, according to a report released this week by the state Department of Public Health.

    Last year’s opioid-related overdose death rate also decreased by 10% to 30.2 per 100,000 people compared to 33.5 in 2022, DPH said.

    Health officials attributed the persistently high death rates to the effects of an “increasingly poisoned drug supply,” primarily with the powerful synthetic opioid fentanyl.

    Fentanyl was present in 90% of the overdose deaths where a toxicology report was available, state officials noted.

    Preliminary data from the first three months of 2024 showed a continued decline in opioid-related overdose deaths, the agency said, with 507 confirmed and estimated deaths, a 9% drop from the same time period last year.

    Gov. Maura Healey said she is “encouraged” by the drop in fatal overdoses but the state needs to continue to focus on “prevention, treatment and recovery efforts to address the overdose crisis that continues to claim too many lives and devastate too many families in Massachusetts.”

    Substance abuse counselors welcomed the declining number of fatal opioid overdoses, but said the data shows that there is still more work to be done to help people struggling with substance use disorders.

    “While the number of opioid-related overdose deaths in the commonwealth remains unacceptably high, it is encouraging to see what we hope is a reversal of a long and painful trend,” Bridgewell President & CEO Chris Tuttle said in a statement. “The time is now to boost public investments and once and for all overcome the scourge of the opioid epidemic.”

    Nationally, there were 107,543 overdose deaths reported in the U.S. in 2023, a 3% decrease from the estimated 111,029 in 2022, according to recently released U.S. Centers for Disease Control and Prevention data.

    In New Hampshire, drug overdose deaths also declined by double digits in 2023, according to figures released in May by the state’s medical examiner and the National Centers for Disease Control.

    There were 430 deaths attributed to overdoses in 2023, an 11.7% decrease from 2022’s 487, according to the data.

    Curbing opioid addiction has been a major focus on Beacon Hill for a number of years with hundreds of millions of dollars being devoted to expanding treatment and prevention efforts.

    The state has set some of the strictest opioid-prescribing laws in the nation, including a cap on new prescriptions in a seven-day period and a requirement that doctors consult a state prescription monitoring database before prescribing an addictive opioid.

    Hundreds of millions of dollars are flowing into the state from multistate settlements with opioid makers and distributors, including $110 million from a $6 billion deal with OxyContin maker Purdue Pharma and the Sackler family.

    Under state law, about 60% of that money will be deposited in the state’s opioid recovery fund, while the remainder will be distributed to communities.

    Earlier this week, House lawmakers were expected to take up a package of bills aimed at improving treatment of substance abuse disorders and reducing opioid overdose deaths.

    The plan would require private insurers to cover emergency opioid overdose-reversing drugs such as naloxone and require drug treatment facilities to provide two doses of overdose-reversal drugs when discharging patients, among other changes.

    Another provision would require licenses for recovery coaches, who are increasingly sent to emergency rooms, drug treatment centers and courtrooms to help addicts get clean.

    Backers of the plan said the goal is to integrate peer recovery coaches more into the state’s health care system, helping addicts who have taken the first steps toward recovery.

    Long-term recovery remains one of the biggest hurdles to breaking the cycle of addiction, they say.

    Christian M. Wade covers the Massachusetts Statehouse for North of Boston Media Group’s newspapers and websites. Email him at cwade@cnhinews.com.

    By Christian M. Wade | Statehouse Reporter

    Source link

  • Report: Injured workers at risk for opioid overdoses

    Report: Injured workers at risk for opioid overdoses

    Workers who are injured on the job are at higher risk for fatal opioid-related overdoses, according to a new study, which calls for renewed efforts to reduce the stigma of drug addiction.

    The report, released Thursday by the state Department of Public Health, found that working-age Massachusetts residents who died between 2011 and 2020 were 35% more likely to have died of an opioid-related overdose if they had previously been injured at work.

    DPH researchers compiled information about individuals’ employment and work-related injury status from their workers’ compensation claims and linked it to data from their death certificates.

    Researchers reviewed the details of 4,304 working-age adults who died between 2011 and 2020 and found at least 17.2% had at least one workplace injury claim and died of an opioid-related overdose, according to the study.

    Public health officials say the study is the first linking the impact of work-related injuries to opioid-related overdose deaths.

    “Occupational injuries can take both a physical and mental toll, and those who suffer injuries at work may be discouraged from seeking help because of stigmatization and fear of losing their jobs,” Health and Human Services Secretary Kate Walsh said in a statement. “Avoiding or delaying care can lead to a preventable overdose death.”

    Walsh called for stepped-up efforts to “eliminate the stigma that accompanies substance use disorder in all sectors of society, including the workplace.”

    The release of the report comes as opioid overdose deaths remain devastatingly high in the Bay State, despite a slight decrease over the past year.

    There were 2,323 confirmed or suspected opioid-related deaths in Massachusetts from Oct. 1, 2022, to Sept. 30, 2023 — eight fewer than the same period in 2021, according to a report released in December by the health department.

    Health officials attributed the persistently high death rates to the effects of an “increasingly poisoned drug supply,” primarily with the powerful synthetic opioid fentanyl.

    Fentanyl was present in 93% of the overdose deaths where a toxicology report was available, state officials noted.

    Curbing opioid addiction has been a major focus on Beacon Hill for a number of years with hundreds of millions of dollars being devoted to expanding treatment and prevention efforts.

    The state has set some of the strictest opioid-prescribing laws in the nation, including a cap on new prescriptions in a seven-day period and a requirement that doctors consult a state prescription monitoring database before prescribing an addictive opioid.

    The Opioid Recovery and Remediation Fund, created by the state Legislature in 2020, has received more than $101 million from settlements with drug makers and distributors over their alleged role in the opioid crisis, according to the Executive Office of Health and Human Services.

    More than 25,000 people have died from opioid-related overdoses in Massachusetts since 2011, according to state records.

    Nationally, fatal drug overdoses fell by roughly 3% in 2023, according data from the U.S. Centers for Disease Control and Prevention.

    But the toll from fatal overdoses in 2023 remained high, claiming 107,543 lives, the federal agency said.

    Fentanyl and other synthetic opioids were responsible for approximately 70% of lives lost, while methamphetamine and other synthetic stimulants are responsible for approximately 30% of deaths, the CDC said.

    “The shift from plant-based drugs, like heroin and cocaine, to synthetic, chemical-based drugs, like fentanyl and methamphetamine, has resulted in the most dangerous and deadly drug crisis the United States has ever faced,” Anne Milgram, head of the Drug Enforcement Administration, said in a recent statement.

    The DEA points to Mexican drug cartels, who it says are smuggling large quantities of fentanyl and other synthetic drugs manufactured in China into the country along the southern border.

    “The suppliers, manufacturers, distributors, and money launderers all play a role in the web of deliberate and calculated treachery orchestrated by these cartels,” she said.

    Christian M. Wade covers the Massachusetts Statehouse for North of Boston Media Group’s newspapers and websites. Email him at cwade@cnhinews.com.

    By Christian M. Wade | Statehouse Reporter

    Source link

  • Can Cannabinoids Help People Wean Off Opioids? | High Times

    Can Cannabinoids Help People Wean Off Opioids? | High Times

    Doctors desperately need tools to battle the opioid epidemic, and they’re turning to cannabinoids for new ways to approach the problem of opioid use disorder (OUD). Recently researchers aimed to create an open-access framework designed to help people wean off and eventually replace opioids with cannabinoids as an alternative. 

    Last August, a study provided a clinical framework for cannabinoids in the battle against the opioid epidemic. The study, entitled “An answered call for aid? Cannabinoid clinical framework for the opioid epidemic,” was published in Harm Reduction Journal.

    Researchers provided an evidence-based clinical framework for the utilization of cannabinoids to treat patients with chronic pain who are dependent on opioids, seeking alternatives, and tapering off of opioids.

    “Based on a comprehensive review of the literature and epidemiological evidence to date, cannabinoids stand to be one of the most interesting, safe, and accessible tools available to attenuate the devastation resulting from the misuse and abuse of opioid narcotics,” researchers wrote. “Considering the urgency of the opioid epidemic and broadening of cannabinoid accessibility amidst absent prescribing guidelines, the authors recommend use of this clinical framework in the contexts of both clinical research continuity and patient care.”

    Recent research has shown a role for CBD in treating cannabis use disorder, and likewise, the compound could be useful in treating OUD. Researchers are also exploring the potential of THC and acidic cannabinoids as well. Cannabis is known anecdotally for the treatment of low-to-moderate amounts of pain despite working in very different ways than opiates.

    The open-access framework includes opioid tapering recommendations that are in accordance with the CDC’s latest clinical practice guidelines for managing opioids for pain. 

    “As opioid deaths continue to be a global problem, patients are increasingly self-medicating with cannabis while researchers struggle to standardize protocols and providers feel uncomfortable recommending cannabinoids amidst absent prescribing guidelines,” researchers wrote. “If we consider cannabis as a harm reduction tool that patients are already using without medical guidance, we can realign our focus to supporting researchers and providers with a clinical framework for standardizing research and recommending cannabinoids more informatively as safe, effective, accessible tools for assisting in the management of chronic pain. To our knowledge, this is one of the first comprehensive evidence-based peer-reviewed clinical frameworks for the safe use of cannabinoid products for chronic pain and OUD.”

    The researchers acknowledged that many of their patients have already begun their own self-guided journey into pain management with cannabinoids.

    The Devastating Toll of Opioid Overdoses

    Opioids continue to wreak havoc on people in America, leading to confusion about who needs powerful opioids and who doesn’t, and overdose deaths continue a steady pace of devastation.

    According to The National Center for Health Statistics (NCHS) under the U.S. Centers for Disease Control and Prevention, drug overdose deaths rose from 2019 to 2021 with over 106,000 drug overdose deaths reported in 2021. Deaths involving synthetic opioids—primarily fentanyl and excluding methadone—continued its death march with 70,601 overdose deaths reported in 2021. Fentanyl in particular kills 150 Americans per day.

    Over-prescription of opioids could be part of the problem. A 2018 longitudinal analysis showed that prescriptions for all opioids in the U.S. fell by 14.4% when medical cannabis dispensaries opened—particularly for hydrocodone and morphine, but also for benzodiazepines, stimulants, and many other medications known to be over-prescribed and addictive. 

    In some states, opioid use disorder is a qualifying condition for the use of medical cannabis. Researchers are still learning about the efficacy of cannabinoids in animal and human trials.

    Studies on Cannabis and Opioid Abuse Vary

    Opioid addiction is a complex phenomenon, and studies vary in their results of whether or not cannabinoids are effective. One study concluded that there is “no evidence that cannabis reduces opioid misuse.”

    According to research published in the American Journal of Psychiatry, researchers instead found “no evidence” showing that cannabis may not be an effective long-term strategy for reducing opioid abuse.

    “There are claims that cannabis may help decrease opioid use or help people with opioid use disorders keep up with treatment. But it’s crucial to note those studies examine short-term impact and focus on treatment of chronic pain and pain management, rather than levels of opioid use in other contexts,” Dr Jack Wilson, the lead author of the study and a postdoctoral research fellow at The Matilda Centre for Research in Mental Health and Substance Use at the University of Sydney in Australia, said in a statement.

    “Our investigation shows that cannabis use remains common among this population, but it may not be an effective long-term strategy for reducing opioid use,” he added.

    Recent studies show the vast potential of cannabis in the fight against the opioid epidemic that continues to ravage the U.S.

    Benjamin M. Adams

    Source link

  • New Study Suggests Cannabis Does Not Help Opioid Use Disorder | High Times

    New Study Suggests Cannabis Does Not Help Opioid Use Disorder | High Times

    A long-term study on opioid addiction and cannabis use found little to no evidence that using cannabis can help addicts reduce or stop their long-term intake of illicit opioids. 

    The study, published in the American Journal of Psychiatry, was led by researchers at the University of Sydney and followed over 600 heroin addicts for up to 20 years, monitoring their cannabis and heroin intake at regular intervals to try and associate a relationship, positive or negative, between the two. 

    “The Australian Treatment Outcome Study (ATOS) recruited 615 people with heroin dependence in 2001 and 2002 and reinterviewed them at 3, 12, 24, and 36 months as well as 11 and 18–20 years after baseline,” the study said. “Heroin and cannabis use were assessed at each time point using the Opiate Treatment Index. A random-intercept cross-lagged panel model analysis was conducted to identify within-person relationships between cannabis use and heroin use at subsequent follow-ups.”

    The results of the study did not find cannabis to be a statistically significant factor in reducing or ceasing a person’s opioid use, despite anecdotal evidence from addicts who claim the plant helps them use less opioids or stop using them altogether. The lead author of the study credited these misconceptions to the way previous studies were conducted, in that they only followed addicts for a short time and did not examine long-term impacts.

    “Our investigation shows that cannabis use remains common among this population, but it may not be an effective long term strategy for reducing opioid use ,” says lead author Dr. Jack Wilson, from The Matilda Centre for Research in Mental Health and Substance Use, at the University of Sydney.

    “There are claims that cannabis may help decrease opioid use or help people with opioid use disorders keep up with treatment. But it’s crucial to note those studies examine short-term impact, and focus on treatment of chronic pain and pain management, rather than levels of opioid use in other contexts.”

    The study actually found data that indicated cannabis use may lead to further opioid use, particularly around the two-three year period of the study. 

    “After accounting for a range of demographic variables, other substance use, and mental and physical health measures, an increase in cannabis use 24 months after baseline was significantly associated with an increase in heroin use at 36 months,” the study said. 

    That said, the study did not go so far as to make a claim that cannabis use may increase heroin use, it merely mentioned the data. Rather, the results section of the study indicated that there simply was not a significant enough relationship in the data to draw any conclusive conclusions, if you will. 

    “Although there was some evidence of a significant relationship between cannabis and heroin use at earlier follow-ups, this was sparse and inconsistent across time points. Overall, there was insufficient evidence to suggest a unidirectional or bidirectional relationship between the use of these substances,” the study said. 

    Dr. Wilson indicated in a press release from the University of Sydney that based on previous available research there does not appear to be a one-size-fits-all solution to opiate addiction, a sentiment which was further reinforced by the results of this long-term study. 

    “Opioid use disorders are complex and unlikely to be resolved by a single treatment,” Dr Wilson said. “The best way to support them is evidence-based holistic approaches that look at the bigger picture, and include physical, psychological, and pharmacotherapy therapies.”

    Previous studies have found somewhat contradictory results compared to this one but as aforementioned, none of those studies were conducted for anywhere near as long. For instance, a study conducted through the University of Connecticut found evidence that cannabis users required less opioids while recovering from a particular major neck surgery. However, the study lasted less than a year and did include data on any possible adverse outcomes that may have occurred after the study, context which is important due to the nature of addicts to sometimes stumble into opiate addiction after having them prescribed for pain.

    Additionally, a 2022 study published in Substance Use and Misuse found that around four out of five patients who were prescribed opioids self-reported in a survey that they were able to reduce or cease their opiate intake using medical cannabis. However, this study was based on one survey and did not follow anyone long-term. That said, there have been several other studies that found similar, positive results. In general, the issue of cannabis as a potential replacement for opioids appears to be a mixed bag until more research is conducted. 

    Patrick Maravelias

    Source link

  • We Have No Drugs to Treat the Deadliest Eating Disorder

    We Have No Drugs to Treat the Deadliest Eating Disorder

    In the 1970s, they tried lithium. Then it was zinc and THC. Anti-anxiety drugs had their turn. So did Prozac and SSRIs and atypical antidepressants. Nothing worked. Patients with anorexia were still unable to bring themselves to eat, still stuck in rigid thought patterns, still chillingly underweight.

    A few years ago, a group led by Evelyn Attia, the director of the Center for Eating Disorders at New York Presbyterian Hospital and the New York State Psychiatric Institute, tried giving patients an antipsychotic drug called olanzapine, normally used to treat schizophrenia and bipolar disorder, and known to cause weight gain as a side effect. Those patients in her study who were on olanzapine increased their BMI a bit more than others who were taking a placebo, but the two groups showed no difference in their cognitive and psychological symptoms. This was the only medication trial for treating anorexia that has shown any positive effect at all, Attia told me, and even then, the effects were “very modest.”

    Despite nearly half a century of attempts, no pill or shot has been identified to effectively treat anorexia nervosa. Anorexia is well known to be the deadliest eating disorder; the only psychiatric diagnosis with a higher death rate is opioid-use disorder. A 2020 review found people who have been hospitalized for the disease are more than five times likelier to die than their peers without it. The National Institutes of Health has devoted more than $100 million over the past decade to studying anorexia, yet researchers have not found a single compound that reliably helps people with the disorder.

    Other eating disorders aren’t nearly so resistant to treatment. The FDA has approved fluoxetine (a.k.a. Prozac) to treat bulimia nervosa and binge-eating disorder (BED); doctors prescribe additional SSRIs off-label to treat both conditions, with a fair rate of success. An ADHD drug, Vyvanse, was approved for BED within two years of the disorder’s official recognition. But when it comes to anorexia, “we’ve tried, I don’t know, eight or 10 fundamentally different kinds of approaches without much in the way of success,” says Scott Crow, an adjunct psychology professor at the University of Minnesota and the vice president of psychiatry for Accanto Health.

    The discrepancy is puzzling to anorexia specialists and researchers. “We don’t fully understand why medications work so differently in this group, and boy, do they ever work differently,” Attia told me. Still, experts have some ideas. Over the past few decades, they have been learning about the changes in brain activity that accompany anorexia. For example, Walter Kaye, the founder and executive director of the Eating Disorders Program at UC San Diego, told me that the neurotransmitters serotonin and dopamine, both of which are involved in the brain’s reward system, seem to act differently in anorexia patients.

    Perhaps some underlying differences in brain chemistry and function play a role in anorexia patients’ extreme aversion to eating. Or perhaps, the experts I spoke with suggested, these brain changes are at least in part a result of patients’ malnourishment. People with anorexia suffer from many effects of malnutrition: Their bones are more brittle; their brain is smaller; their heart beats slower; their breath comes shorter; their wounds fail to heal. Maybe their neurons respond differently to psychoactive drugs too.

    Psychiatrists have found that many patients with anorexia don’t improve with treatment even when medicines are prescribed for conditions other than their eating disorder. If an anorexia patient also has anxiety, for example, taking an anti-anxiety drug would likely fail to relieve either set of symptoms, Attia told me. “Time and again, investigators have found very little or no difference between active medication and placebo in randomized controlled trials,” she said. The fact that fluoxetine seems to help anorexia patients avoid relapse—but only when it’s given after they’ve regained a healthy weight—also supports the notion that malnourished brains don’t respond so well to psychoactive medication. (In that case, the effect might be especially acute for people with anorexia nervosa, because they tend to have lower BMIs than people with other eating disorders.)

    Why exactly this would be true remains a mystery. Attia noted that proteins and certain fats have been shown to be crucial for brain function; get too little of either, and the brain might not metabolize drugs in expected ways. Both she and Kaye suggested a possible role for tryptophan, an amino acid that humans get only from food. Tryptophan is converted into serotonin (among other things) when we release insulin after a meal, Kaye said, but in anorexia patients, whose insulin levels tend to be low, that process could end up off-kilter. “We suspect that that might be the reason why [SSRIs] don’t work very well,” he said, though he emphasized that the theory is very speculative.

    In the absence of meaningful pharmacologic intervention, doctors who treat anorexia rely on methods such as nutrition counseling and psychotherapy. But even non-pharmaceutical interventions, such as cognitive behavioral therapy, are more effective at treating bulimia and binge-eating disorder than anorexia. Studies from around the world have shown that as many as half of people with anorexia relapse.

    Colleen Clarkin Schreyer, a clinical psychologist at Johns Hopkins University, sees both patients with anorexia nervosa and those with bulimia nervosa, and told me that the former can be more difficult to treat—“but not just because of the fact that we don’t have any medication to help us along. I often find that patients with anorexia nervosa are more ambivalent about making behavior change.” Bulimia patients, she said, tend to feel shame about their condition, because binge eating is stigmatized and, well, no one likes vomit. But anorexia patients might be praised for skipping meals or rapidly losing weight, despite the fact that their behaviors can be just as dangerous over the long term as binging and vomiting.

    Researchers are still trying to find substances that can help anorexia patients. Crow told me that case studies testing a synthetic version of leptin, a naturally occurring human hormone, have produced interesting data. Meanwhile, some early research into using psychedelics, including ketamine, psilocybin, and ayahuasca, suggests that they may relieve some symptoms in some cases. But until randomized, controlled trials are conducted, we won’t know whether or how well any psychedelic really works. Kaye is currently recruiting participants for such a study of psilocybin, which is planned to have multiple sites in the U.S. and Europe.

    Pharmaceutical companies just don’t seem that enthusiastic about testing treatments for anorexia, Crow said. “I think that drug makers have taken to heart the message that the mortality is high” among anorexia patients, he told me, and thus avoid the risk of having deaths occur during their clinical trials. And drug development isn’t the only area where the study of anorexia has fallen short. Research on eating disorders tends to be underfunded on the whole, Crow said. That stems, in part, from “a widely prevailing belief that this is something that people could or should just stop … I wish that were how it works, frankly. But it’s not.”

    Rachel Gutman-Wei

    Source link

  • University of Kentucky physicians push for standard-of-care opioid treatment for incarcerated patients

    University of Kentucky physicians push for standard-of-care opioid treatment for incarcerated patients

    Newswise — In a recently published commentary, UK HealthCare physicians call for standard-of-care treatment for opioid use disorder (OUD) among patients who are incarcerated.

    The viewpoint article by Anna-Maria South, M.D., Laura Fanucchi, M.D., and Michelle Lofwall, M.D., published in JAMA April 24 highlights the barriers to initiating medication for opioid use disorder (MOUD) among people who are incarcerated.

    For patients with opioid use disorder, medications such as buprenorphine and methadone are considered by the medical community as standard of care treatments, as they alleviate withdrawal symptoms, reduce cravings and pain, decrease infections, and lower the risk of mortality. However, the use of these medications is often restricted in U.S. prisons and jails, with only a few states mandating their use in the carceral system. 

    The physicians’ article draws attention to the significant moral distress experienced by doctors when patients who are incarcerated need to be hospitalized due to serious medical complications resulting from untreated opioid use disorder, but they are unable to provide them with the best treatment.

    The article also highlights the fact that denying patients standard-of-care treatments because they are incarcerated violates medical ethics, constitutional amendments and the Americans with Disabilities Act (ADA) and emphasizes the need for physician advocacy.

    “Incarcerated people with opioid use disorder are among the most vulnerable patient populations that also have the least ability to advocate for themselves,” said South, an assistant professor in UK College of Medicine’s Division of Hospital Medicine and an attending physician on the Addiction Consult and Education Services. “We as physicians have a powerful voice for advocacy to make substantial change. We need to educate ourselves on the rights that our patients have and where we can go to advocate for them.”

    South is the paper’s first author and UK’s 2022 Bell Addiction Medicine Scholar. South’s work on this article was supported by the Bell Alcohol and Addictions Scholar Program.

    Read the full JAMA article here.

    UK HealthCare is the hospitals and clinics of the University of Kentucky. But it is so much more. It is more than 10,000 dedicated health care professionals committed to providing advanced subspecialty care for the most critically injured and ill patients from the Commonwealth and beyond. It also is the home of the state’s only National Cancer Institute (NCI)-designated cancer center, a Level IV Neonatal Intensive Care Unit that cares for the tiniest and sickest newborns, the region’s only Level 1 trauma center and Kentucky’s top hospital ranked by U.S. News & World Report.  

    As an academic research institution, we are continuously pursuing the next generation of cures, treatments, protocols and policies. Our discoveries have the potential to change what’s medically possible within our lifetimes. Our educators and thought leaders are transforming the health care landscape as our six health professions colleges teach the next generation of doctors, nurses, pharmacists and other health care professionals, spreading the highest standards of care. UK HealthCare is the power of advanced medicine committed to creating a healthier Kentucky, now and for generations to come. 

    University of Kentucky

    Source link

  • Canada province decriminalizes hard drugs in new bid to combat opioid crisis

    Canada province decriminalizes hard drugs in new bid to combat opioid crisis

    Ottawa — A Canadian province on Tuesday decriminalized the possession of small amounts of cocaine, heroin, fentanyl and other hard drugs in a radical policy shift to address an opioid overdose crisis that has killed thousands. Adults found with up to 2.5 grams of these drugs, rather than face jail or fines, will be provided with information on how to access addiction treatment programs.

    Police will also not seize their drugs.

    Sellers and traffickers of hard drugs, however, will continue to face criminal prosecution during the three-year British Columbia pilot project.

    “The situation has never been more urgent,” Addictions Minister Carolyn Bennett told a news conference on the eve of the new rules taking effect.

    “The effects of this public health crisis have devastated communities across British Columbia and across Canada,” she said. When the measure was announced last May, she’d suggested it could be expanded to other provinces.


    Fatal fentanyl overdoses on the rise in the U.S.

    09:59

    British Columbia is the epicenter of a crisis that has seen more than 10,000 overdose deaths since it declared a public health emergency in 2016. That represents about six people dying each day from toxic drug poisoning in the province of five million people, topping COVID-19 deaths at the onset of the pandemic.

    Nationwide the number of fatalities has topped 30,000.

    Officials hope the change in policy will remove the stigma associated with drug use that keeps people from seeking help, and foster the notion that addiction is a health issue.

    Supervised consumption sites in the DTES give addicts who use fentanyl, opioids, crystal methamphetamine and other drugs a place to use
    Medics with the Vancouver Fire Rescue Services attend to a man who overdosed on drugs in the Downtown Eastside (DTES) neighborhood, in a May 5, 2022 file photo in Vancouver, British Columbia.

    Gary Coronado/Los Angeles Times/Getty


    British Columbia’s chief public health officer Bonnie Henry said stigma and shame around using drugs “drives people to hide their addictions.”

    “That means that many people are dying alone,” she said.

    Kathryn Botchford, whose husband Jason died of a drug overdose in 2019, said she had no idea he’d even been using drugs.

    “When I discovered how he died, I thought there must be a mistake. Jason doesn’t do drugs. We have three young kids and he knows the risks,” she said. “But I was wrong. He died alone using an illegal substance.”

    Botchford said she initially kept his cause of death secret, even from their children. “His secret became my secret.”

    But eventually, she said, “I realized that… I was unconsciously creating shame.”

    243 crosses cover the lot on the south west corner of Brady and Paris Streets as part of Crosses for Change that memorialize victims in the overdose and opioid crisis
    Eric sits on his skateboard as he visits the cross that commemorates his girlfriend Jada – one of 243 crosses that cover a lot as part of the Crosses for Change project memorializing victims of the opioid overdose crisis in Sudbury, Ontario, Canada, May 9, 2022.

    Steve Russell/Toronto Star/Getty


    Canada has spent more than Can$800 million (US$600 million) to try to stem the opioid crisis, including on addiction treatment, Naloxone supplies and opening 39 supervised drug consumption sites across Canada.

    Bennett pointed to successes such as the more than 42,000 overdoses reversed at safe injection sites, and more than 209,000 individuals referred to health and social services in recent years.

    But she acknowledged also “that access to treatment remains a gap” that is being worked on.

    Source link

  • Some addiction treatment centers turn big profits by scaling back care

    Some addiction treatment centers turn big profits by scaling back care

    Near the end of his scheduled three-month stay at a rehab center outside Austin, Texas, Daniel McKegney was forced to tell his father in North Carolina that he needed more time and more money, he recently recalled.

    His father had already received bills from BRC Recovery totaling about $150,000 to cover McKegney’s treatment for addiction to the powerful opioid fentanyl, according to insurance statements shared with KHN. But McKegney, 20, said he found the program “suffocating” and wasn’t happy with his care.

    He was advised against the long-term use of Suboxone, a medication often recommended to treat opioid addiction, because BRC does not consider it to be a form of abstinence. After an initial five-day detox period last April, McKegney’s care plan mostly included a weekly therapy session and 12-step group meetings, which are available for free around the country.

    McKegney said a BRC staffer recommended he stay a fourth month and even sat in on the call to his dad.

    “They used my life and [my] father’s love for me to pull another 20 grand out of him,” said McKegney, who told KHN he began using fentanyl again after the costly stay.

    BRC did not respond to specific concerns raised by McKegney. But in an emailed statement, Mandy Baker, president and chief clinical officer of BRC Healthcare, said that many of the complaints patients and former employees shared with KHN are “no longer accurate” or were related to COVID safety measures. 

    But addiction researchers and private equity watchdogs said models like the one used by BRC — charging high patient fees without guaranteeing access to evidence-based care — are common throughout the country’s addiction treatment industry.

    The model and growing demand are why addiction treatment has become increasingly attractive to private equity firms looking for big returns. And they’re banking on forecasts that predict the market will grow by $10 billion — doubling in size — by the end of the decade as drug overdose and alcohol-induced death rates mount.

    “There is a lot of money to be made,” said Eileen O’Grady, research and campaign director at the Private Equity Stakeholder Project, a watchdog nonprofit that tracks private equity investment in health care, housing, and other industries. “But it’s not necessarily dovetailing with high-quality treatment.”

    In 2021, 127 mergers and acquisitions took place in the behavioral health sector, which includes treatment for substance use disorders, a rebound after several years of decline, according to investment banking firm Capstone Partners. Private equity investment drove much of the activity in an industry that is highly fragmented and rapidly growing, and has historically had few guardrails to ensure patients are getting appropriate care.

    Nashville Recovery Center building
    BRC Recovery, a private equity-backed addiction treatment company, bought Nashville Recovery Center in 2021. Private equity investment has driven much of the recent activity in substance abuse treatment, an industry that is highly fragmented and has historically had few guardrails to ensure patients are getting appropriate care.

    Blake Farmer for KHN


    Roughly 14,000 treatment centers dot the country. They’ve proliferated as addiction rates rise and as health insurance plans are required to offer better coverage of drug and alcohol treatment. The treatment options vary widely and are not always consistent with those recommended by the federal Substance Abuse and Mental Health Services Administration. While efforts to standardize treatment advance, industry critics say private equity groups are investing in centers with unproven practices and cutting services that, while unprofitable, might support long-term recovery.

    Baker said the company treats people who have been unsuccessful in other facilities and does so with input from both clients and their families.

    Private equity skimps on the known standards

    Centers that discourage or prohibit the use of FDA-approved medications for the treatment of substance use disorder are plentiful, but in doing so they do not align with the American Society of Addiction Medicine’s guidelines on how to manage opioid use disorder over the long term.

    Suboxone, for example, combines the pain reliever buprenorphine and the opioid-reversal medication naloxone. The drug blocks an overdose while also reducing a patient’s cravings and withdrawal symptoms.

    “It is inconceivable to me that an addiction treatment provider purporting to address opioid use disorder would not offer medications,” said Robert Lubran, a former federal official and chairman of the board at the Danya Institute, a nonprofit that supports states and treatment providers.

    Residential inpatient facilities, where patients stay for weeks or months, have a role in addiction treatment but are often overused, said Brendan Saloner, an associate professor of health policy and management at Johns Hopkins Bloomberg School of Public Health.

    Many patients return to drug and alcohol use after staying in inpatient settings, but studies show that the use of medications can decrease the relapse rate for certain addictions. McKegney said he now regularly takes Suboxone.

    “The last three years of my life were hell,” he said.

    Along with access to medications, high-quality addiction treatment usually requires long-term care, according to Shatterproof, a nonprofit focused on improving addiction treatment. And, ideally, treatment is customized to the patient. While the “Twelve Steps” program developed by Alcoholics Anonymous may help some patients, others might need different behavioral health therapies.

    But, when looking for investments, private equity groups focus on profit, not necessarily how well the program is designed, said Laura Katz Olson, a political science professor at Lehigh University who wrote a book about private equity’s investment in American health care.

    With health care companies, investors often cut services and trim staff costs by using fewer and less trained workers, she said. Commonly, private equity companies buy “a place that does really excellent work, and then cut it down to bare bones,” Olson said. During his stay, McKegney said, outings to see movies or go to a lake abruptly stopped, food went from poke bowls and pork tenderloin to chili that tasted like “dish soap,” and staff turnover was high.

    Nearly three years ago, BRC landed backing from NewSpring Capital and Veronis Suhler Stevenson, two private equity firms with broad portfolios. Their holdings include a payroll processor, a bridal wear designer, and a doughnut franchise. With the fresh funds, BRC started an expansion push and bought several Tennessee treatment facilities.

    NewSpring Capital and Veronis Suhler Stevenson did not respond to emails and phone calls from KHN.

    High prices and low overhead = big business

    Before the sale to BRC, Nashville Recovery Center co-founder Ryan Cain said, roughly 80% of the center’s offerings were free. Anyone could drop by for 12-step meetings, to meet a sponsor, or just play pool. But the new owners focused on a new high-end sober living program that cost thousands of dollars per month and relied on staffers who were in recovery themselves.

    “You have a perfect breeding ground to be able to take advantage of a lot of really good-hearted, well-intentioned people,” said former Nashville Recovery Center staffer Mitzi Dawn, who is in recovery and now works at another treatment facility. Dawn hosted a “Sing and Share” that was canceled soon after the takeover.

    Mitzi Dawn
    Mitzi Dawn was on staff at Nashville Recovery Center and left after the center was acquired by BRC Recovery and her popular “Sing and Share” event was canceled. She says she worried about her colleagues, since most are in recovery as she is.

    Blake Farmer for KHN


    In 2021, Nanci Milam, 48, emptied her 401(k) retirement fund to go through the sober living program and tackle her alcohol addiction. She had been sober for only six months when she was hired as a house manager, overseeing some of the same residents she had gone through the program with. She had to handle other residents’ medications, which she said she could have abused. Milam said she was fortunate to maintain sobriety. 

    “I think it served their need. And I was ambitious. But it should not have happened,” said Milam, adding that she left because the company hadn’t helped her start her certification as a drug counselor as promised.

    A licensing violation reported to Tennessee regulators in late 2021 involved a staffer who was later fired for having sex with a resident in a storage area. And KHN obtained a copy of a 911 call placed in August 2022 — after a resident drank half a bottle of mouthwash — during which a staffer admitted there was no nurse on-site, which some other states require.

    Removing the burden from consumers

    The regulations of treatment providers largely focus on health and safety rather than clinical guidelines. Only a handful of states, including New York and Massachusetts, require that licensed addiction treatment centers offer medication for opioid use disorder and follow other best practices.

    “We have a huge issue in the field where licensing standards don’t comport with what we know to be the most effective quality-of-care standards,” said Michael Botticelli, former director of the Office of National Drug Control Policy during the Obama administration and a member of a clinical advisory board for private equity-backed Behavioral Health Group. Some organizations, including Shatterproof, guide patients toward appropriate care. The federal and state governments largely direct public funds to centers that meet clinical quality-of-care standards.

    But access to treatment is limited, and desperate patients and their families often don’t know where to turn. State or federal regulators aren’t policing claims from rehab facilities, like the “99% success rate” touted by BRC.

    “We cannot put the burden on patients and their families” to navigate the system, said Johns Hopkins’ Saloner. “My heart really breaks for people who have thrown thousands of their dollars at programs that are bogus.”

    When her niece was ready for inpatient rehab in summer 2020, Marina said that sending her to BRC was a “knee-jerk reaction.” Marina, a physician in Southern California, requested to be identified only by her middle name to protect the privacy of her niece, who suffers from alcohol addiction.

    She had researched the facility three years earlier but didn’t investigate deeper because she was worried her niece would change her mind. BRC advertised success stories on the television show “Dr. Phil” and posted affirmations on social media.

    Marina agreed to BRC’s upfront cost of $30,000 a month for a three-month stay in Texas, which she paid for out-of-pocket because her niece lacked insurance. She allowed KHN to review some of her niece’s pharmacy and treatment bills.

    Marina said she paid for a fourth month, but said ultimately the program didn’t help her niece, who remains “horribly sick.” She said her niece felt constant guilt and shame at rehab. Marina thought there was inadequate medical oversight, and said the program “nickeled and dimed” her for additional services, like physicians’ visits, that she thought would be included.

    “It almost doesn’t matter if you are educated and intelligent,” Marina said. “When it’s your loved one, you are just desperate.”


    KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

    Source link

  • Easing prescription rules for opioid treatment meds did not increase overdose deaths, study finds

    Easing prescription rules for opioid treatment meds did not increase overdose deaths, study finds

    A new study shows that reducing restrictions on buprenorphine, a medication that can treat opioid use disorder, did not lead to an increase in overdose deaths involving the treatment. The findings may help allay concerns that making buprenorphine more widely available could lead to more overdose deaths. 

    Buprenorphine and similar medications, like methadone and Suboxone, are opioid agonists that reduce withdrawal symptoms and cravings. Compared to methadone, buprenorphine has a lower potential for misuse and overdose, making it the most accessible of all the options, but it remains “substantially underused,” the study says. 

    There are restrictions on who can prescribe buprenorphine and where it can be obtained. It remains classified as a Schedule III controlled substance, meaning one with a moderate to low risk of dependence. Previously, buprenorphine had to be prescribed in a clinical setting by a prescriber registered with the Drug Enforcement Administration. Recent policy changes have removed the requirement commonly known as the “X waiver,” which had limited how many patients a provider could prescribe buprenorphine for.

    During the coronavirus pandemic, federal rule changes allowed qualified clinicians to remotely prescribe buprenorphine, even to new patients, removing a requirement for in-person evaluations. That change will remain in place until the public health emergency declared in April 2020 is ended by the federal government. 

    To determine the effect of these policy changes, the federal researchers who conducted the study looked at 89,111 overdose deaths reported by 32 jurisdictions from July 2019, before the changes began, until June 2021, after about 15 months of the new policy. Of those 89,111 overdose deaths, 74,474 involved opioids. 

    Of the opioid-related deaths, just 1,995 cases involved buprenorphine. In total, buprenorphine was found in 2.2% of all drug overdose deaths and 2.6% of opioid-involved overdose deaths. 

    Despite an increase in overdose deaths from 2019 to 2021, buprenorphine overdose deaths did not increase. There was some fluctuation between July 2019 and June 2021, but death rates either decreased or stayed stable, the researchers found.

    “Our findings suggest that expanded prescribing was not associated with a disproportionate number of deaths involving buprenorphine,” researchers said in the study, which was was a collaborative effort between the National Institute on Drug Abuse and the Centers for Disease Control and Prevention.

    “Nonetheless, although rare, overdose deaths involving buprenorphine highlight the importance of overdose prevention and support for those using buprenorphine both under medical supervision or outside of treatment for SUD [substance use disorder] or pain,” they wrote.  

    The researchers also said that more equitable access to the medications and other “harm reduction strategies” are needed to help address the overdose crisis.

    Another finding of the study was that less than a quarter of buprenorphine-involved overdose deaths were people receiving treatment for opioid use disorder at the time of their death, and even fewer — about 20% — were specifically taking medications to help with the problem. 

    Only 3.2% of people who died of opioid overdoses were receiving treatment at the time. 

    This “stark finding,” researchers said, highlights “the need to expand access to evidence-based treatment, particularly medications for OUD; improve treatment retention; and support long-term recovery.” 

    A major part of why buprenorphine has had restrictions is the concern that it could be “diverted,” or given by the person receiving the prescription to someone else. The study did look at this issue, and found that while there may be some misuse, it was likely because people were trying to “suppress withdrawal and self-treat” their addiction “in the absence of formal treatment access.” This study, along with prior research, concluded that it was unlikely that people were misusing buprenorphine to experience a “high.” 

    The researchers said their findings were consistent with a 2022 study that reported no association between COVID-era prescribing flexibility for methadone-based treatment and methadone-involved overdose deaths. In most cases, patients who use methadone have to go to clinics daily for their dose, but during the pandemic patients were allowed to receive up to one month’s supply of the medication at a time. 

    Source link